Published in Obesity and Diabetes Week, September 15th, 2003
[helv]During the year ended March 31, 2003, the company decided to fully focus its management and capital resources on the development of markets for Sucanon, the company's type II diabetes treatment. Accordingly, the company closed its lotions and creams operation, sharply reducing ongoing overhead costs and monthly losses. Simultaneously, with the sale of equipment related to the lotions and creams operation, the company's secured debt has been reduced by $1.5 million.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.